{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:28:36Z","timestamp":1792189716900,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Roche Diagnostics International Ltd"},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00798-8","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T06:48:38Z","timestamp":1752994118000},"page":"2011-2031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Performance of the Elecsys CSF pTau181\/A\u03b242 Ratio for Concordance with Tau-PET in Two Independent Cohorts"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0112","authenticated-orcid":false,"given":"Ruben","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9591-5710","authenticated-orcid":false,"given":"Matteo","family":"Tonietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9050-3282","authenticated-orcid":false,"given":"Clara","family":"Quijano-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6757-4664","authenticated-orcid":false,"given":"Myrto","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha C.","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0841-5580","authenticated-orcid":false,"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"798_CR1","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u2013821.","DOI":"10.1002\/alz.13809"},{"key":"798_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clinbiochem.2019.04.015","volume":"72","author":"M Zv\u011b\u0159ov\u00e1","year":"2019","unstructured":"Zv\u011b\u0159ov\u00e1 M. Clinical aspects of Alzheimer\u2019s disease. Clin Biochem. 2019;72:3\u20136.","journal-title":"Clin Biochem"},{"issue":"2","key":"798_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"798_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/brainsci11101258","volume":"11","author":"GP Paraskevas","year":"2021","unstructured":"Paraskevas GP, Kapaki E. Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in the era of disease-modifying treatments. Brain Sci. 2021;11(10):1258.","journal-title":"Brain Sci"},{"issue":"12","key":"798_CR5","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, et al. Alzheimer disease as a clinical-biological construct\u2014an international working group recommendation. JAMA Neurol. 2024;81(12):1304\u201311.","journal-title":"JAMA Neurol"},{"issue":"18","key":"798_CR6","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/hbm.24782","volume":"40","author":"A Chandra","year":"2019","unstructured":"Chandra A, Valkimadi PE, Pagano G, Cousins O, Dervenoulas G, Politis M. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer\u2019s disease and mild cognitive impairment. Hum Brain Mapp. 2019;40(18):5424\u201342.","journal-title":"Hum Brain Mapp"},{"issue":"Suppl. 1","key":"798_CR7","doi-asserted-by":"publisher","first-page":"20s","DOI":"10.2967\/jnumed.121.263196","volume":"63","author":"C Groot","year":"2022","unstructured":"Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022;63(Suppl. 1):20s-s26.","journal-title":"J Nucl Med"},{"issue":"6","key":"798_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484\u201396.","journal-title":"Lancet Neurol"},{"issue":"8","key":"798_CR9","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"Suppl. 1","key":"798_CR10","doi-asserted-by":"publisher","first-page":"13s","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"M Chapleau","year":"2022","unstructured":"Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med. 2022;63(Suppl. 1):13s-s19.","journal-title":"J Nucl Med"},{"key":"798_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","volume":"94","author":"L Rice","year":"2017","unstructured":"Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease\u2014a systematic review. Eur J Radiol. 2017;94:16\u201324.","journal-title":"Eur J Radiol"},{"issue":"7","key":"798_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamaneurol.2023.1323","volume":"80","author":"R Smith","year":"2023","unstructured":"Smith R, H\u00e4gerstr\u00f6m D, Pawlik D, et al. Clinical utility of tau positron emission tomography in the diagnostic workup of patients with cognitive symptoms. JAMA Neurol. 2023;80(7):749\u201356.","journal-title":"JAMA Neurol"},{"issue":"8","key":"798_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78(8):961\u201371.","journal-title":"JAMA Neurol"},{"issue":"2","key":"798_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/WCO.0000000000001035","volume":"35","author":"G Cassinelli Petersen","year":"2022","unstructured":"Cassinelli Petersen G, Roytman M, Chiang GC, Li Y, Gordon ML, Franceschi AM. Overview of tau PET molecular imaging. Curr Opin Neurol. 2022;35(2):230\u20139.","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"798_CR15","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","volume":"26","author":"M Bucci","year":"2021","unstructured":"Bucci M, Chiotis K, Nordberg A. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26(10):5888\u201398.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"798_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"2","key":"798_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/ph14020110","volume":"14","author":"CVML Jie","year":"2021","unstructured":"Jie CVML, Treyer V, Schibli R, Mu L. Tauvid\u2122: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals (Basel). 2021;14(2):110.","journal-title":"Pharmaceuticals (Basel)"},{"key":"798_CR18","unstructured":"European Medicines Agency (EMA). Summary of product characteristics: Tauvid 800 MBq\/mL solution or injection; Tauvid 1 900 MB\/mL solution for injection. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tauvid-epar-product-information_en.pdf. Accessed 5 Mar 2025."},{"key":"798_CR19","unstructured":"Eli Lilly. US prescribing information: TAUVID\u2122 (flortaucipir F 18 injection), for intravenous use. 02\/2024 ed. 2024. https:\/\/pi.lilly.com\/us\/tauvid-uspi.pdf. Accessed 21 Mar 2025."},{"issue":"5","key":"798_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0250-2","volume":"51","author":"JC Lee","year":"2019","unstructured":"Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019;51(5):1\u201310.","journal-title":"Exp Mol Med"},{"issue":"1","key":"798_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Bendlin BB. Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26(1):296\u2013308.","journal-title":"Mol Psychiatry"},{"issue":"15","key":"798_CR22","doi-asserted-by":"publisher","first-page":"8598","DOI":"10.3390\/ijms23158598","volume":"23","author":"M Dulewicz","year":"2022","unstructured":"Dulewicz M, Kulczy\u0144ska-Przybik A, Mroczko P, Kornhuber J, Lewczuk P, Mroczko B. Biomarkers for the diagnosis of Alzheimer\u2019s disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria. Int J Mol Sci. 2022;23(15):8598.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"798_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H. CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol. 2003;2(10):605\u201313.","journal-title":"Lancet Neurol"},{"issue":"12","key":"798_CR24","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00702-002-0763-y","volume":"109","author":"C Mulder","year":"2002","unstructured":"Mulder C, Schoonenboom SN, Wahlund LO, et al. CSF markers related to pathogenetic mechanisms in Alzheimer\u2019s disease. J Neural Transm (Vienna). 2002;109(12):1491\u20138.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"798_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000090631","volume":"21","author":"AK Wallin","year":"2006","unstructured":"Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer\u2019s disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord. 2006;21(3):131\u20138.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"798_CR26","doi-asserted-by":"publisher","unstructured":"Prakash RS, McKenna MR, Gbadeyan O, Andridge R, Scharre DW, for the Alzheimer\u2019s Disease Neuroimaging Initiative. p-tau\/A\u03b242 ratio associates with cognitive decline in Alzheimer\u2019s disease, mild cognitive impairment, and cognitively unimpaired older adults. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.10.13.20211375v1. Accessed 23 Apr 2025.","DOI":"10.1101\/2020.10.13.20211375v1"},{"issue":"2","key":"798_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","volume":"148","author":"N Warmenhoven","year":"2025","unstructured":"Warmenhoven N, Salvad\u00f3 G, Janelidze S, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain. 2025;148(2):416\u201331.","journal-title":"Brain"},{"issue":"1","key":"798_CR28","doi-asserted-by":"publisher","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","volume":"9","author":"K Blennow","year":"2019","unstructured":"Blennow K, Shaw LM, Stomrud E, et al. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1\u201342), pTau and tTau CSF immunoassays. Sci Rep. 2019;9(1):19024.","journal-title":"Sci Rep"},{"issue":"2","key":"798_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1515\/cclm-2022-0516","volume":"61","author":"K Blennow","year":"2023","unstructured":"Blennow K, Stomrud E, Zetterberg H, et al. Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer\u2019s disease. Clin Chem Lab Med. 2023;61(2):234\u201344.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"798_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-020-00595-5","volume":"12","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, Ward L, Burnham SC, et al. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther. 2020;12(1):36.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"798_CR31","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470\u201381.","journal-title":"Alzheimers Dement"},{"key":"798_CR32","unstructured":"Roche Diagnostics. Press release: Roche Alzheimer's disease Cerebrospinal Fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis. 2022. https:\/\/www.roche.com\/media\/releases\/med-cor-2022-12-08. Accessed Mar 2025."},{"key":"798_CR33","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2024-1476","author":"H Schinke","year":"2025","unstructured":"Schinke H, F\u00f6rnvik Jonsson M, et al. Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer\u2019s disease assessment: findings from the Apollo study. Clin Chem Lab Med. 2025. https:\/\/doi.org\/10.1515\/cclm-2024-1476.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"798_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12226","volume":"7","author":"CJ Weber","year":"2021","unstructured":"Weber CJ, Carrillo MC, Jagust W, et al. The Worldwide Alzheimer\u2019s Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. Alzheimers Dement (N Y). 2021;7(1):e12226.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"798_CR35","volume":"12","author":"O Hansson","year":"2020","unstructured":"Hansson O, Rutz S, Zetterberg H, et al. Pre-analytical protocol for measuring Alzheimer\u2019s disease biomarkers in fresh CSF. Alzheimers Dement (Amst). 2020;12(1):e12137. (Erratum in: Alzheimers Dement (Amst). 2021;13(1):e76).","journal-title":"Alzheimers Dement (Amst)"},{"key":"798_CR36","unstructured":"University of Southern California. Alzheimer\u2019s Disease Neuroimaging Initiative 3 (ADNI3) Protocol. 2016. https:\/\/adni.loni.usc.edu\/wp-content\/themes\/freshnews-dev-v2\/documents\/clinical\/ADNI3_Protocol.pdf?%20https:\/\/biofinder.se\/%20AND%20https:\/\/adni.loni.usc.edu\/.  Accessed 14 July 2025."},{"issue":"4","key":"798_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamaneurol.2020.5505","volume":"78","author":"M Lu","year":"2021","unstructured":"Lu M, Pontecorvo MJ, Devous MD Sr, et al. Aggregated tau measured by visual interpretation of Flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease: results from 2 phase\u00a0III clinical trials. JAMA Neurol. 2021;78(4):445\u201353.","journal-title":"JAMA Neurol"},{"issue":"7","key":"798_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD Sr, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829\u201339.","journal-title":"JAMA Neurol"},{"issue":"8","key":"798_CR39","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77(8):955\u201365.","journal-title":"JAMA Neurol"},{"issue":"8","key":"798_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24(8):1112\u201334.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"798_CR41","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-019-04496-0","volume":"47","author":"R Smith","year":"2020","unstructured":"Smith R, Sch\u00f6ll M, Leuzy A, et al. Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948. Eur J Nucl Med Mol Imaging. 2020;47(2):342\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"798_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.18773\/austprescr.2003.082","volume":"26","author":"J Attia","year":"2003","unstructured":"Attia J. Moving beyond sensitivity and specificity: using likelihood ratios to help interpret diagnostic tests. Aust Prescr. 2003;26:111\u20133.","journal-title":"Aust Prescr"},{"key":"798_CR43","unstructured":"US Food and Drug Administration. Guidance for industry and FDA staff: statistical guidance on reporting results from studies evaluating diagnostic tests. 2007. https:\/\/www.fda.gov\/media\/71147\/download. Accessed 27 Mar 2025."},{"issue":"8","key":"798_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/0895-4356(91)90128-V","volume":"44","author":"DL Simel","year":"1991","unstructured":"Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44(8):763\u201370.","journal-title":"J Clin Epidemiol"},{"key":"798_CR45","unstructured":"R Core\u00a0Team. R: a language and environment for statistical computing. 2021. https:\/\/www.r-project.org\/. Accessed 22 Apr 2025."},{"key":"798_CR46","unstructured":"Roche Diagnostics GmbH. Elecsys Phospho-Tau (181P) CSF [method sheet]. 2.0. Mannheim, Germany. 2023. https:\/\/elabdoc-prod.roche.com\/eLD\/api\/downloads\/f842bdce-738f-ee11-2191-005056a772fd?countryIsoCode=XG. Accessed 23 Apr 2025."},{"issue":"9","key":"798_CR47","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Mu\u00f1oz L, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815\u201324.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"798_CR48","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Reimand J, Smith R, et al. Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021;13(8):e14398.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"798_CR49","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s00259-021-05246-x","volume":"48","author":"D Altomare","year":"2021","unstructured":"Altomare D, Caprioglio C, Assal F, et al. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. Eur J Nucl Med Mol Imaging. 2021;48(7):2200\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"S2","key":"798_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/alz.088853","volume":"20","author":"G Piga","year":"2025","unstructured":"Piga G, Gonzalez-Ortiz F, Yuksekel I, et al. Plasma BD-tau as a specific correlate of disease severity and dynamic across the Alzheimer\u2019s disease spectrum. Alzheimer Dement. 2025;20(S2):e088853.","journal-title":"Alzheimer Dement"},{"key":"798_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-025-00835-z","author":"R Ossenkoppele","year":"2025","unstructured":"Ossenkoppele R, Salvad\u00f3 G, Janelidze S, et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat Aging. 2025. https:\/\/doi.org\/10.1038\/s43587-025-00835-z.","journal-title":"Nat Aging"},{"key":"798_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03617-7","author":"K Horie","year":"2025","unstructured":"Horie K, Salvad\u00f3 G, Koppisetti RK, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03617-7.","journal-title":"Nat Med"},{"issue":"1","key":"798_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13195-025-01684-z","volume":"17","author":"C Boccalini","year":"2025","unstructured":"Boccalini C, Peretti DE, Scheffler M, et al. Sex differences in the association of Alzheimer\u2019s disease biomarkers and cognition in a multicenter memory clinic study. Alzheimers Res Ther. 2025;17(1):46.","journal-title":"Alzheimers Res Ther"},{"issue":"Suppl 9","key":"798_CR54","first-page":"S49","volume":"19","author":"S Nemes","year":"2023","unstructured":"Nemes S, Logan PE, Manchella MK, et al. Sex and APOE \u03b54 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(Suppl 9):S49-63.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"798_CR55","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1093\/brain\/awaa327","volume":"143","author":"R Smith","year":"2020","unstructured":"Smith R, Strandberg O, Mattsson-Carlgren N, et al. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain. 2020;143(12):3805\u201315.","journal-title":"Brain"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00798-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:03:23Z","timestamp":1758369803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00798-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland and Eli Lilly and Company, Indianapolis, IN, USA. The Elecsys Phospho-Tau (181P) CSF and Elecsys \u03b2-Amyloid (1\u201342) CSF II immunoassays used in the study were manufactured and supplied by Roche Diagnostics International Ltd. Ruben Smith has received consultancy and speaker fees from Eli Lilly, Novo Nordisk, Roche, and Triolab. Clara Quijano-Rubio and Myrto Andreadou are full-time employees of Roche Diagnostics International Ltd, Rotkreuz, Switzerland. Christopher M. Rank is a full-time employee of Roche Diagnostics GmbH, Penzberg, Germany, and shareholder of F. Hoffmann-La Roche Ltd. Matteo Tonietto and Gregory Klein are full-time employees and shareholders of F. Hoffmann-La Roche Ltd. Samantha C. Burnham is a full-time employee of Eli Lilly and Company and holds company stocks. Leslie Shaw, Sebastian Palmqvist, Niklas Mattsson-Carlgren, and Erik Stomrud have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted according to the principles of the Declaration of Helsinki. All samples from the BioFINDER-2 and ADNI-2\/3 studies were collected under separate collection study protocols, under the control of the original study investigators with regard to the informed consent forms and recruitment. Ethics approval was received for the Swedish BioFINDER-2 study from the Regional Ethics Committee in Lund, Sweden. Written informed consent was obtained from each subject prior to enrolment into the ADNI-2\/3 and Swedish BioFINDER-2 studies. All sample information and all required clinical information were pseudonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}